Compare JAGX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAGX | CDT |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.4M |
| IPO Year | 2014 | N/A |
| Metric | JAGX | CDT |
|---|---|---|
| Price | $2.81 | $0.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 62.4K | ★ 12.2M |
| Earning Date | 04-07-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,511,000.00 | N/A |
| Revenue This Year | $61.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.37 |
| 52 Week High | $8.00 | $11.00 |
| Indicator | JAGX | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 35.84 |
| Support Level | $1.76 | N/A |
| Resistance Level | $4.13 | $0.73 |
| Average True Range (ATR) | 0.27 | 0.23 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 72.63 | 1.87 |
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.